Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease

Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease

Bibliographic Details
Main Authors:	Keith A. Betts, PhD, Sasikiran Nunna, PhD, Retesh Kumar, MD, Xiaoyu Nie, PhD, Ancilla W. Fernandes, PhD
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Series:	Kidney Medicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S259005952400013X

Similar Items

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
by: Michael Lioudis, et al.
Published: (2023-06-01)

Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease
by: William P. Martin, MBChB, MSc, et al.
Published: (2019-06-01)

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
by: Sans-Atxer L, et al.
Published: (2018-01-01)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
by: Raina R, et al.
Published: (2022-09-01)

Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
by: Manuel A. Anderegg, et al.
Published: (2020-03-01)

Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
by: Fei Liu, et al.
Published: (2021-07-01)

Changes in Kidney and Liver Volumes in Patients With Autosomal Dominant Polycystic Kidney Disease Before and After Dialysis Initiation
by: Tatsuya Suwabe, MD, MSc, PhD, et al.
Published: (2023-02-01)

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
by: Yaerim Kim, et al.
Published: (2023-05-01)

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
by: Kyohei Kunizawa, et al.
Published: (2018-03-01)

Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?
by: Hee Sun Beak, et al.
Published: (2023-12-01)

Pelvic organ prolapse in women with autosomal dominant polycystic kidney disease under tolvaptan treatment
by: Cristina Sango, et al.
Published: (2023-11-01)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
by: Shinya Nakatani, et al.
Published: (2020-02-01)

Educational Case: Autosomal Recessive Polycystic Kidney Disease
by: Ashley S. Hafer MPA, et al.
Published: (2017-08-01)

UMOD-related autosomal dominant tubulointerstitial kidney disease: an unfavourable novel mutation
by: Pedro Viaño Nogueira, MD, et al.
Published: (2023-05-01)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
by: Olivier Devuyst, et al.
Published: (2017-11-01)

Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease
by: Jung Hyun Shin, et al.
Published: (2023-05-01)

Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease
by: Javier Naranjo, et al.
Published: (2022-09-01)

The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis
by: Xuanwei Li, et al.
Published: (2023-11-01)

The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis
by: Xuanwei Li, et al.
Published: (2023-11-01)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial
by: Muto S, et al.
Published: (2017-10-01)

The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
by: Kiyotaka Uchiyama, et al.
Published: (2021-09-01)

Geriatric Opioid Harm Reduction: Interprofessional Student Learning Outcomes
by: Faika Zanjani PhD, et al.
Published: (2020-04-01)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]
by: Muto S, et al.
Published: (2018-07-01)

Treatment of autosomal recessive and autosomal dominant polycystic kidney disease
by: E. F. Andreeva, et al.
Published: (2019-05-01)

A Simple Tool for Communicating the Benefits and Harms of Health Interventions
by: Michelle McDowell PhD, et al.
Published: (2016-08-01)

Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease
by: Shuma Hirashio, et al.
Published: (2018-06-01)

Treatment persistence to tolvaptan in patients with autosomal dominant polycystic kidney disease: a secondary use of data analysis of patients in the IMADJIN® dataset
by: Mark Thomas, et al.
Published: (2021-12-01)

Tolvaptan, Kidney Function Decline, and Potential Confounding by Muscle Wasting
by: Dion Groothof, BSc, et al.
Published: (2023-10-01)

Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy
by: Mai Yamazaki, et al.
Published: (2024-02-01)

Are you ready to accompany autosomal dominant polycystic kidney disease patients in their treatment journey? Real practice for selecting rapid progressors and treatment with tolvaptan
by: Yeonsoon Jung, et al.
Published: (2023-06-01)

The importance of the number of antihypertensives in the progression of autosomal dominant polycystic kidney disease
by: Víctor Martínez Jiménez, et al.
Published: (2021-05-01)

Regulation of Dendritic Cell Functions against Harmful Respiratory Pathogens by a Cysteinyl Leukotrienes Receptor Antagonist
by: Hiroto Matsuse M.D., Ph.D., et al.
Published: (2012-01-01)

The Benefits and Harms of Lung Cancer Screening in Individuals With Comorbidities
by: Minal S. Kale, MD, MPH, et al.
Published: (2024-03-01)

Autosomal Dominant Polycystic Kidney Disease
by: Schwenger Vedat, et al.
Published: (1999-01-01)

The effect of spatial learning on the number of astrocytes in the Rat’s dentate gyrus
by: Mehrdad Jahanshahi (PhD), et al.
Published: (2008-10-01)

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
by: Angela Maria Pellegrino, et al.
Published: (2019-11-01)

Treatment of Deliberate Self-harm Scars with Rotated Thin-skin Graft and Minced-skin Graft
by: Kento Takaya, MD, et al.
Published: (2020-08-01)

Educational Case: Autosomal Recessive Inheritance
by: D. Yitzchak Goldstein MD, et al.
Published: (2017-08-01)

Association of parental supply of alcohol with adolescent drinking, alcohol-related harms, and alcohol use disorder symptoms: a prospective cohort study
by: Prof Richard P Mattick, PhD, et al.
Published: (2018-02-01)

The Priorities of Iranian Male Adolescents Health Needs
by: Elham Zare PhD, et al.
Published: (2017-07-01)